TOLL FREE: 888.88.INFECT
PHONE: 517.536.8210
FAX: 517.536.8205

THE WELLHOFF CENTER
7190 S. BROOKLYN RD.
JACKSON, MI 49201

TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions

Dermal Infection – Deep Wound

A dermal infection involves the dermis, the dense inner layer of skin beneath the epidermis. These skin infections are caused by microbial invasion, and the presentation and severity of infection vary based on time of treatment, the invading pathogen, and the immune response it elicits. In severe cases, dermal infections can progress to the underlying soft tissue or become systemic. Our dermal studies assess the pharmacodynamic relationship between novel antimicrobial agents and infection outcome.

Procedure
We have established a deep wound infection model in mice. A biopsy punch is used to create a full-thickness 6 mm wound over the thoracic spine area on the dorsal surface and bacterial broth is inoculated directly into the wound. Test article may be administered via topical application, oral gavage (PO), subcutaneous (SC), intraperitoneal (IP), or intravenous (IV) injection. The route, duration, and frequency of dosing can be customized to meet client needs. Endpoints for this study include CFU burden in harvested skin. Pharmacokinetic profiling, blood chemistry, and histology are available upon request.

Pathogens
TransPharm has validated a deep wound dermal infection model using the following pathogens:

  • Acinetobacter baumannii
    • ATCC 17961
    • MMX 6970
  • Staphylococcus aureus (MRSA)
    • USA300

Additional validations are available upon request.